Dupixent® (dupilumab)approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
- Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo
- Patients treated with Dupixent achieved rapid itch reduction as early as three weeks after start of therapy, with significant improvements at 16 weeks sustained through one year
- Dupixent is now a treatment option for the approximately 80,000 infants and young children living with uncontrolled severe atopic dermatitis in Europe
- Milestone marks third Dupixent European Commission approval in the past four months
Paris and Tarrytown, N.Y.March21, 2023. The European Commission (EC) has approved Dupixent® (dupilumab) in…